Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22402387 | 0.77 | POLB (0.41) | POLBSTING1ALDH1A1KDM4EMEN1 | |
| SCHEMBL21140749 | 0.70 | CYP3A4 (0.38) | ALDH1A1 | |
| SCHEMBL24721757 | 0.69 | NLRP3 (0.40) | ALDH1A1 | |
| SCHEMBL13656198 | 0.68 | TP53 (0.44) | POLBALDH1A1RORCMEN1KMT2A | |
| SCHEMBL12356967 | 0.67 | CNR2 (0.42) | ALDH1A1MEN1KMT2A | |
| SCHEMBL21016363 | 0.66 | HTT (0.35) | POLBALDH1A1MEN1KMT2A | |
| SCHEMBL762353 | 0.64 | ALDH1A1 (0.45) | POLBALDH1A1KMT2A | |
| SCHEMBL24359090 | 0.64 | SLC6A2 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL18329549 | 0.63 | MAPT (0.43) | POLBALDH1A1MEN1KMT2A | |
| SCHEMBL13151212 | 0.63 | ALDH1A1 (0.44) | POLBALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | POLB 4812/4885STING1 3904/4885ALDH1A1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.